BioSpace News Archive

Biotechnology company signs CMO to produce metric tons of rare cannabinoids for nutraceutical, skincare, and other consumer health and wellness products

PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, announced today that the Risk Underlying Rural Areas Longitudinal Study (RURAL) has selected PixCell’s novel miniaturized, portable hematology analyzer, HemoScreen™

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that members of the management team will participate in the 10th Annual SVB Leerink Global Healthcare Conference.

Full Year Sales Up 60.9% - Fourth Quarter Sales Up 90.5% - Full Year Subscriptions Up 25% 2021 Outlook Revenue Raised, Key Strategic Initiatives Reaffirmed

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the first participant was dosed in a Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, in Ghana.

Hoth intends to pursue FDA Expedited Programs, such as Breakthrough Designation, pending generation of future clinical study data for HT-001

RedHawk Holdings Corp., a diversified holding company primarily engaged in sales and distribution of medical devices, announced gross revenues for the three and six month periods ended December 31, 2020 were $370,871 and $835,104, respectively.

FDA Approves EndoClot ® Hemostat to Manage GI Bleeding A Unique Product to Rapidly and Reliably Control Bleeding During GI Procedures

Re-Vana Therapeutics, a specialty ocular therapeutic and drug delivery company that specializes in the development of photo-crosslinked drug delivery technologies for both biologic and small molecules, today announced the appointment of Michael Nash as Chief Commercial Officer and David Shima, PhD, as Vice President of Research and Development.

UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the following virtual conferences in March 2021: Cowen 41 st Annual Health Care Conference